 Home > Active Ingredient News > Immunology News > Positive progress in tumor electric field therapy for lung cancer Zai Lab owns rights in Greater China

Positive progress in tumor electric field therapy for lung cancer Zai Lab owns rights in Greater China

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

future cancer treatment

aquatic development group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Novocure announced that its Tumor Treating Fields (TTF) has made positive progress in a pivotal Phase 3 clinical trial for the treatment of patients with non-small cell lung cancer.

Tumor treatment electric field is a low-intensity alternating electric field, which can affect the movement of specific cell components during cell mitosis and disrupt mitosis.

This innovative treatment has been approved by the US FDA and used in combination with chemotherapy for the first-line treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma.

This pivotal phase 3 clinical trial aims to evaluate the combination of tumor electric field therapy with immune checkpoint inhibitors or docetaxel, compared with immune checkpoint inhibitors or docetaxel monotherapy, in treatment level 4 ( stage 4) The effect in patients with non-small cell lung cancer.

Note: The original text has been deleted

Reference materials:

[1] Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Positive progress in tumor electric field therapy for lung cancer Zai Lab owns rights in Greater China

04-17

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Positive progress in tumor electric field therapy for lung cancer Zai Lab owns rights in Greater China

Related Articles

Positive progress in tumor electric field therapy for lung cancer Zai Lab owns rights in Greater China